The lawsuit, filed in the United States District Court for the District of Massachusetts, covers shareholders who acquired Ardelyx securities between January 13, 2025, and August 6, 2026. According to the complaint, the firm repeatedly assured the market that its commercial strategy successfully bypassed patient-access barriers. However, these claims allegedly masked growing difficulties with stringent prior authorization and step edit requirements that hampered new-patient starts.

The discrepancy surfaced after the market closed on August 6, 2026, when Ardelyx downgraded its full-year 2026 revenue guidance for IBSRELA and withdrew its long-term projections for XPHOZAH, citing intensifying utilization-management processes. The following trading session, the company’s stock price fell from $4.87 to $4.00, prompting institutional investors to assess potential recoveries.

Legal counsel from Levi & Korsinsky, LLP noted that institutional holders—including pension funds and asset managers—must evaluate their purchase activity to determine if they qualify for lead plaintiff status. Under the Private Securities Litigation Reform Act of 1995, the deadline to apply for appointment as lead plaintiff is November 16, 2026. While institutional participation can provide direct oversight regarding case strategy and counsel selection, eligible class members who do not take procedural action remain entitled to share in any potential settlement.